Top 10 Medical AI Companies to Buy According to Analysts

3. NeoGenomics, Inc. (NASDAQ:NEO)

Stock Upside Potential: 82.75%

Number of Hedge Fund Holders: 17

NeoGenomics, Inc. (NASDAQ:NEO) is one of the top 10 medical AI companies to buy according to analysts. On July 30, the company announced the launch of NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test.

The launch of PanTracer positions NeoGenomics at the forefront of the precision oncology market. The noninvasive test is designed to support therapy selection as it provides access to biomarker information when tissue samples are insufficient or unavailable. The test can analyze over 500 genes, including MSI and bTMB, to deliver actionable insights.

“As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It’s a strategic milestone that underscores our commitment to sustainable growth and clinical leadership,” said Tony Zook, Chief Executive Officer.

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion liquid biopsy market. It also strengthens its prospects in delivering deep insights to more patients across diverse care settings.

NeoGenomics, Inc. (NASDAQ:NEO) is a cancer diagnostics and pharma services company. It leverages AI in several key areas of oncology testing and diagnostics. It’s also actively involved in developing and implementing AI-powered tools for digital pathology.